Get the Stockscreener App
1.385
1.07%
-0.015
Neumora Therapeutics Inc stock is traded at $1.385, with a volume of 59,054.
It is down -1.07% in the last 24 hours and down -20.40% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.40
Open:
$1.42
24h Volume:
59,054
Relative Volume:
0.02
Market Cap:
$226.77M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.5464
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-7.05%
1M Performance:
-20.40%
6M Performance:
-88.49%
1Y Performance:
-90.85%
1-Day Range:
$1.37
$1.426
1-Week Range:
$1.26
$1.48
52-Week Range:
$1.26
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.385 | 226.77M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.84 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.68 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.35 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.72 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.99 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
ROSEN, THE FIRST FILING FIRM, Encourages Neumora - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA - GlobeNewswire Inc.
Lead Plaintiff Deadline Approaching in NMRA: Kessler Topaz - GlobeNewswire
Lead Plaintiff Deadline Approaching in NMRA: Kessler Topaz Meltzer & Check, LLP Reminds Investors a Securities Fraud Class Action Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) - TradingView
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Neumora Therapeutics, Inc.(NMRA) Shareholders - ACCESS Newswire
Class Action Filed Against Neumora Therapeutics, Inc. - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - PR Newswire
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) See - GuruFocus.com
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. - GlobeNewswire
NMRA CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investorsa Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) | FinancialContent - Financial Content
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-03-12 | Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
2025-03-11 | Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class ActionNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNMRA - PR Newswire
NASDAQ: NMRA Lawsuit Alert: Investors with substantial Losses from shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) should contact the Shareholders Foundation - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - GlobeNewswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Equities Analysts Issue Forecasts for NMRA Q1 Earnings - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Downgraded to Market Perform Rating by William Blair - Defense World
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
2025-03-10 | Shareholders that Lost Money on Neumora Therapeutics, Inc. (NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:NMRA | Press Release - Stockhouse Publishing
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNMRA - ACCESS Newswire
2025-03-10 | NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:NMRA | Press Release - Stockhouse Publishing
Neumora Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationNMRA - ACCESS Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - Morningstar
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - StreetInsider.com
Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - ACCESS Newswire
Neumora stock rating cut to Market Perform at William Blair - Investing.com
Neumora stock holds Buy rating and $18 target from H.C. Wainwright - Investing.com
William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform - MarketBeat
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by William Blair to Market Perform - MarketBeat
William Blair Downgrades Neumora Therapeutics to Market Perform From Outperform -March 10, 2025 at 07:50 am EDT - Marketscreener.com
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: - GlobeNewswire
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds ... - The Bakersfield Californian
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar
HC Wainwright Issues Optimistic Estimate for NMRA Earnings - MarketBeat
Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World
What is William Blair's Forecast for NMRA Q1 Earnings? - MarketBeat
2025-03-09 | Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora - GlobeNewswire
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA) - ACCESS Newswire
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-03-09 | NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:NMRA | Press Release - Stockhouse Publishing
Neumora Therapeutics (NASDAQ:NMRA) Stock Rating Lowered by Guggenheim - Defense World
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):